The current standard of care is summarized and emerging strategies aimed at overcoming constraints aimed at overcoming these constraints are critically examined, including locoregional delivery technologies, immunotherapy, biomarker-defined precision approaches, and adaptive clinical trial designs.
Abstract
Glioblastoma remains the most aggressive primary malignant brain tumor in adults, with survival largely unchanged despite advances in molecular diagnostics and supportive care. Therapeutic failure reflects fundamental biological and anatomical barriers, including intratumoral heterogeneity, an immunosuppressive tumor microenvironment, and restricted drug delivery across the blood-brain barrier. In this Review, we summarize the current standard of care and critically examine emerging strategies aimed at overcoming these constraints, including locoregional delivery technologies, immunotherapy, biomarker-defined precision approaches, and adaptive clinical trial designs. We highlight key translational and clinical studies shaping the field and discuss principles for developing more effective, integrated therapeutic paradigms.
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. Although recent World Health Organization classifications integrating molecular features have improved diagnostic precision, therapeutic outcomes for IDH-wild-type glioblastoma remain dismal. Standard treatment with radiothera...
J. Blaquier, M. Lim-Fat, M. I. de la Fuente· Neurotherapeutics· 0 citations
Glioblastoma remains one of the most aggressive and difficult-to-treat brain tumors. Although immunotherapy has transformed the management of several cancers, its clinical impact in glioblastoma has been limited. This review summarizes the main immunotherapeutic approaches currently investigated, including immune check...
D. Slavkov, Svetoslava Troyanova Slavkova· Cancer Immunology Connect· 0 citations
This comprehensive review delves into recent advances in modern therapeutic approaches that aim to enhance the efficacy of conventional treatments for rare brain metastases from breast cancer and systematically evaluates emerging strategies such as advanced drug delivery technologies, including nanoparticles (NPs), pol...
Ghazala Muteeb, Aya Y El-Sayed, Mohamed S. AboHoussien et al.· SLAS discovery : advancing l...· 0 citations
This review systematically summarizes recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal-oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli-responsive nano-...
Yu Guo, Keqiang Lu, Wenmiao Luo et al.· Wiley Interdisciplinary Revi...· 1 citation
This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non-invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.
Yu-Ran Feng, Yu-Xue Cao, Maria Kavallaris et al.· Advances in Materials· 0 citations
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumo...
Daan A. Sluijter, Rianne van Garderen, Ilse van Haveren et al.· Neuro-Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
